STOCKHOLM--(BUSINESS WIRE)-- As a consequence of that the results of the ChronSeal® study will not be made public until May 27th Kringle Inc. in Japan has given ChronTech Pharma (STO:CTEC) a six months’ extension, i.e. until the 31st of December 2010, of its option to buy back in ownership of the ChronSeal®.
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.
This information was brought to you by Cision http://www.cisionwire.com
ChronTech Pharma AB
Anders Vahlne, +46 8 5858 1313
CEO and Head of Research
Mobile phone: +46 709 28 05 28
KEYWORDS: Europe Sweden
INDUSTRY KEYWORDS: Health Biotechnology Infectious Diseases Medical Devices Pharmaceutical Other Health Medical Supplies